Related Experiment Video
Updated: Aug 12, 2025

An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices
Published on: April 11, 2018
Cholinergic neurons in the basal forebrain are involved in behavioral abnormalities associated with Cul3 deficiency:
Maximiliano Rapanelli1, Wei Wang1, Edward Hurley2,3
1Department of Physiology and Biophysics, Jacobs School of Medicine, University at Buffalo, The State University of New York, Buffalo, USA.
Abstract:
Loss-of-function mutations of the gene Cul3 have been identified as a risk factor for autism-spectrum disorder (ASD), but the pathogenic mechanisms are not well understood. Conditional Cul3 ablation in cholinergic neurons of mice (ChatCRECul3F/+) recapitulated ASD-like social and sensory gating phenotypes and caused significant cognitive impairments, with diminished activity of cholinergic neurons in the basal forebrain (BF). Chemogenetic inhibition of BF cholinergic neurons in healthy mice induced similar social and cognitive deficits. Conversely, chemogenetic stimulation of BF cholinergic neurons in ChatCRECul3F/+ mice reversed abnormalities in sensory gating and cognition. Cortical hypofunction was also found after ChAT-specific Cul3 ablation and stimulation of cholinergic projections from the BF to the prefrontal cortex (PFC) mitigated cognitive deficits. Overall, we demonstrate that cholinergic dysfunction due to Cul3 deficiency is involved in ASD-like behavioral abnormalities, and that BF cholinergic neurons are particularly critical for cognitive component through their projections to the PFC.
Insights
Loss-of-function Cul3 gene mutations are linked to autism spectrum disorder (ASD). This study shows that cholinergic neuron dysfunction in the basal forebrain contributes to ASD-like behaviors and cognitive deficits.
Area of Science:
- Neuroscience
- Genetics
- Developmental Biology
Background:
- Loss-of-function mutations in the Cul3 gene are associated with autism spectrum disorder (ASD).
- The precise pathogenic mechanisms linking Cul3 to ASD remain unclear.
- Cholinergic system dysfunction is implicated in neurodevelopmental disorders.
Purpose of the Study:
- To investigate the role of Cul3 in cholinergic neuron function.
- To elucidate the contribution of basal forebrain (BF) cholinergic neurons to ASD-like phenotypes.
- To explore therapeutic potential of modulating BF cholinergic activity.
Main Methods:
- Conditional Cul3 ablation in mouse cholinergic neurons (ChatCRECul3F/+).
- Assessment of social behavior, sensory gating, and cognitive function.
- Chemogenetic manipulation of BF cholinergic neuron activity.
Main Results:
- Cul3 ablation in cholinergic neurons induced ASD-like social and sensory gating deficits and cognitive impairments.
- Inhibition of BF cholinergic neurons in healthy mice mimicked these deficits.
- Stimulation of BF cholinergic neurons reversed sensory gating and cognitive abnormalities in Cul3-deficient mice.
- Cortical hypofunction was observed, and BF-PFC cholinergic projections modulated cognitive deficits.
Conclusions:
- Cholinergic dysfunction resulting from Cul3 deficiency contributes to ASD-like behavioral abnormalities.
- Basal forebrain cholinergic neurons are critical for cognitive functions, particularly through their projections to the prefrontal cortex (PFC).
- Targeting BF cholinergic neurons may offer a therapeutic strategy for ASD-related cognitive impairments.
Related Concept Videos
Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Role of Cerebellum and Prefrontal Cortex in Memory
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cholinergic Neurons: Neurotransmission
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Direct-Acting Cholinergic Agonists: Pharmacokinetics

